The Transient Receptor Potential Vanilloid type-2 (TRPV2) channel exhibits oncogenicity in different types of cancers. TRPV2 is implicated in signaling pathways that mediate cell survival, proliferation, and metastasis. In leukemia and bladder cancer, the oncogenic activity of TRPV2 was linked to alteration of its expression profile. In multiple myeloma patients, TRPV2 overexpression correlated with bone tissue damage and poor prognosis. In prostate cancer, TRPV2 overexpression was associated with the castration-resistant phenotype and metastasis. Loss or inactivation of TRPV2 promoted glioblastoma cell proliferation and increased resistance to CD95-induced apoptotic cell death. TRPV2 overexpression was associated with high relapse-free survival in triple-negative breast cancer, whereas the opposite was found in patients with esophageal squamous cell carcinoma or gastric cancer. Another link was found between TRPV2 expression and either drug-induced cytotoxicity or stemness of liver cancer. Overall, these findings validate TRPV2 as a prime candidate for cancer biomarker and future therapeutic target.

中文翻译：

---

TRPV2：癌症生物标志物和潜在的治疗靶点

Transient Receptor Potential Vanilloid type-2 (TRPV2) 通道在不同类型的癌症中表现出致癌性。TRPV2 与介导细胞存活、增殖和转移的信号通路有关。在白血病和膀胱癌中，TRPV2 的致癌活性与其表达谱的改变有关。在多发性骨髓瘤患者中，TRPV2 过表达与骨组织损伤和不良预后相关。在前列腺癌中，TRPV2 过表达与去势抵抗表型和转移有关。TRPV2 的缺失或失活促进了胶质母细胞瘤细胞增殖并增加了对 CD95 诱导的细胞凋亡的抵抗力。TRPV2 过表达与三阴性乳腺癌的高无复发存活率相关，而食管鳞癌或胃癌患者则相反。在 TRPV2 表达与药物诱导的细胞毒性或肝癌干性之间发现了另一个联系。总体而言，这些发现证实了 TRPV2 是癌症生物标志物和未来治疗目标的主要候选者。